Informed Choice - Compass
Reason given: Business decision to terminate the study early. Primary endpoint will not be assessed.
Key facts
- Where
- Annapolis, Aurora, Brooklyn, Charleston, Charlotte, Chicago, Columbia, Columbus, Harrisburg, Houston, Jackson, Jacksonville, Jersey City, La Vista, Los Angeles, Marietta, Miami, New Orleans, Niagara Falls, Oklahoma City, Panama City, Pharr, Philadelphia, Phoenix, Pleasant View, Port Hueneme, Pottstown, Providence, Rockville, Rosedale, Roy, Saginaw, South Ogden, Spring, St Louis, Sugarland, Suwanee, and Union City, United StatesSee the 39 sites
Where in United States
- Annapolis Internal MedicineAnnapolis, United StatesNo longer taking part
- Skylight Health GroupAurora, United StatesNo longer taking part
- Ellipsis Research Group, LLCBrooklyn, United StatesNo longer taking part
- Medical University of South CarolinaCharleston, United StatesNo longer taking part
- Onsite Clinical Solutions, LLCCharlotte, United StatesNo longer taking part
- Sheridan Medical Center, S.CChicago, United StatesNo longer taking part
- SPICA Clinical ResearchColumbia, United StatesNo longer taking part
- ClinCept, LLCColumbus, United StatesNo longer taking part
- Skylight HealthHarrisburg, United StatesNo longer taking part
- Clear Brook Medical AssociatesHouston, United StatesNo longer taking part
- The Jackson Clinic, PAJackson, United StatesNo longer taking part
- Skylight Health GroupJacksonville, United StatesNo longer taking part
- Alliance Community Healthcare, INCJersey City, United StatesNo longer taking part
- Barrett ClinicLa Vista, United StatesNo longer taking part
- Biopharma InformaticLos Angeles, United StatesNo longer taking part
- Pivotal Clinical Research & Associates, LLCMarietta, United StatesNo longer taking part
- I.V.A.M Clinical & Investigational CenterMiami, United StatesNo longer taking part
- ITB ResearchMiami, United StatesNo longer taking part
- Ascension DePaul Community Services of New OrleansNew Orleans, United StatesNo longer taking part
- Niagara Falls Memorial Medical CenterNiagara Falls, United StatesNo longer taking part
- Hightower Clinical OKCOklahoma City, United StatesNo longer taking part
- Emerald Coast OBGYNPanama City, United StatesNo longer taking part
- BioPharma InformaticPharr, United StatesNo longer taking part
- Mercado Medical PracticePhiladelphia, United StatesNo longer taking part
- Absolute Clinical ResearchPhoenix, United StatesNo longer taking part
- Ogden Clinic - Mountain ViewPleasant View, United StatesNo longer taking part
- Saviers Medical GroupPort Hueneme, United StatesNo longer taking part
- Pottstown Medical Specialists IncPottstown, United StatesNo longer taking part
- Center for Medical Research, LLCProvidence, United StatesNo longer taking part
- Advanced Primary and Geriatric CareRockville, United StatesNo longer taking part
- Laurelton Heart Specialist, PCRosedale, United StatesNo longer taking part
- Ogden Clinic Grand ViewRoy, United StatesNo longer taking part
- Valley OB-GYN Clinic, PCSaginaw, United StatesNo longer taking part
- South Ogden Family MedicineSouth Ogden, United StatesNo longer taking part
- Valena Medical ResearchSpring, United StatesNo longer taking part
- St. Louis Medical ProfessionalsSt Louis, United StatesNo longer taking part
- A & U Family MedicineSugarland, United StatesNo longer taking part
- Herman Clinical Research LLCSuwanee, United StatesNo longer taking part
- North Hudson Community Action CorporationUnion City, United StatesNo longer taking part
Trial details
- Who runs it
- Exact Sciences Corporation
- Trial code
- NCT05246839
- Record updated
- 10 November 2025
- Original description
The primary objective of this study is to evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices on CRC screening rates and time adherent to CRC guidelines. The results will not be posted because the study terminated early and the primary endpoint was not analyzed.Read full original descriptionShow less
Informed Choice Intervention for Colorectal Cancer Screening: Compass
The primary objective of this study is to evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices on CRC screening rates and time adherent to CRC guidelines. The results will not be posted because the study terminated early and the primary endpoint was not analyzed.
Inclusion: Participant is 45 to 70 years of age, inclusive; Participant presents for a primary care appointment; Participant understands the study procedures and can provide informed consent to participate in the study and authorization for release of relevant protected health information (PHI) to the study Investigator; Participant has never been screened for CRC.
Exclusion: Participant has a family history of CRC in at least one first- or second-degree relative diagnosed prior to age 60 and/or at least 2 first-degree relatives diagnosed with CRC at any age; Participant is current with CRC screening, including gFOBT or FIT within the preceding 12 months, Cologuard within the preceding 3 years, flexible sigmoidoscopy or CT colonography within the preceding 5 years, or colonoscopy within the preceding 10 years. Participants can be enrolled up to 3 months prior to screening due date; Participant has a personal history of CRC or colonic adenomatous or sessile serrated polyps; Participant has a personal history of inflammatory bowel disease; Participant has a personal diagnosis or family history of any of the following conditions:; Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome),; Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome"),; Other hereditary cancer syndromes including, but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis; Participant has a diagnosis of Cronkhite-Canada Syndrome; Participant has any condition that in the opinion of the Investigators should preclude participation in the study, including comorbid illnesses precluding endoscopic evaluation or that limit life expectancy to less than 10 years; Participant has symptoms or signs that require immediate, or near-term referral for diagnostic or therapeutic colonoscopy; Participant is due for CRC screening within three months and is already scheduled for colonoscopy.